Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-26-368244

Chief Development Officer sold 50,160 shares at an average $50.47 ($2,531,582)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Yeleswaram Krishnaswamy Chief Development Officer 2026-08-24 Sale 10b5-1 −13,160 $50.00 $657,978 232,862 D
Yeleswaram Krishnaswamy Chief Development Officer 2026-08-25 Sale 10b5-1 −20,799 $50.31 $1,046,421 212,063 D
Yeleswaram Krishnaswamy Chief Development Officer 2026-08-25 Sale 10b5-1 −16,201 $51.06 $827,184 195,862 D
Open-market sales · 50,160 sh · avg $50.47 · $2,531,582
Loading xslF345X06/ownership.xml…